RESEARCH TRIANGLE PARK, N.C., Oct. 14 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics (Nasdaq: TLCR) announced today that the U.S. Food and Drug Administration ...
Immune globulin (human) 1g/10mL, 2.5g/25mL, 5g/50mL, 10g/100mL, 20g/200mL, 40g/400mL; soln for IV or SC infusion; preservative- and sucrose-free. Immunoglobulins are fractionated blood products made ...
RESEARCH TRIANGLE PARK, N.C. (April 23, 2009) — Talecris Biotherapeutics, Inc. today announced the publication of the health-related quality of life results from the largest clinical trial ever ...
Study finds that long-term treatment with Gamunex can significantly improve health-related quality of life in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). CIDP is a ...
New Subcutaneous Administration Provides another Mode of Delivery For Patients with Primary Immunodeficiency RESEARCH TRIANGLE PARK , N.C., Oct 14, 2010 /PRNewswire via COMTEX/ -- Talecris ...
Status: Grifols said January 18 that it will begin a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on Gamunex ®-C, and containing anti-SARS-CoV-2 polyclonal ...
announced today that the U.S. Food and Drug Administration approved Gamunex®-C, 10% Caprylate/Chromatography Purified) for subcutaneous administration in the treatment of primary immunodeficiency. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results